| __timestamp | Blueprint Medicines Corporation | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 1802274 |
| Thursday, January 1, 2015 | 14456000 | 2512761 |
| Friday, January 1, 2016 | 19218000 | 2894488 |
| Sunday, January 1, 2017 | 27986000 | 8096274 |
| Monday, January 1, 2018 | 47928000 | 7985229 |
| Tuesday, January 1, 2019 | 96388000 | 8994597 |
| Wednesday, January 1, 2020 | 157743000 | 29772000 |
| Friday, January 1, 2021 | 195293000 | 33907000 |
| Saturday, January 1, 2022 | 237374000 | 26579000 |
| Sunday, January 1, 2023 | 295141000 | 49868547 |
| Monday, January 1, 2024 | 359272000 |
Unleashing the power of data
In the competitive world of biotechnology, managing expenses is crucial for success. Blueprint Medicines Corporation and Verona Pharma plc, two prominent players, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Blueprint Medicines has seen a staggering increase of over 3,600% in SG&A expenses, peaking at nearly $295 million in 2023. This reflects their aggressive expansion and investment in growth. In contrast, Verona Pharma's SG&A expenses have grown by approximately 2,670%, reaching nearly $50 million in the same year. This more conservative increase suggests a strategic focus on sustainable growth. These trends highlight the diverse strategies within the biotech sector, where companies balance between rapid expansion and steady progress. Understanding these financial dynamics offers valuable insights into the operational priorities and future trajectories of these innovative firms.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Blueprint Medicines Corporation
Teva Pharmaceutical Industries Limited and Verona Pharma plc: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Catalent, Inc. and Verona Pharma plc
Blueprint Medicines Corporation and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation or Amneal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Soleno Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Verona Pharma plc vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.
Verona Pharma plc vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.